Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
Stryker Corporation reported solid first-quarter 2026 results with net sales of $6.02 billion, up from $5.87 billion a year earlier, driven mainly by MedSurg and Neurotechnology growth. Net earnings rose to $745 million, and diluted EPS increased to $1.93.
Adjusted diluted EPS was $2.60, down 8.5% from 2025 as adjusted operating margin contracted to 21.1%. A March 11, 2026 cybersecurity incident caused idle production time, pressuring gross margin to 63.3% and segment margins, though manufacturing operations and commercial systems have been restored. Cash from operations improved to $581 million, while the company repaid $1.0 billion of maturing notes and ended the quarter with $2.97 billion in cash and marketable securities.
Suri Rajeev reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Rajeev Suri received an equity award in the form of restricted stock units. On May 6, 2026, he was granted 762 RSUs that were reported as common stock, with no cash paid as this is compensation rather than a market purchase.
The RSUs will vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock. Following this grant, Suri directly owns 7,190 shares of Stryker common stock.
Stryker Corporation director Ronda E. Stryker received an equity award of 762 Restricted Stock Units (RSUs) of Stryker common stock. The award is compensation, not an open-market purchase, and increases her directly held shares to 1,322 after the grant.
The RSUs vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027, and each RSU converts into one share of common stock upon settlement. In addition to her direct holdings, she has significant indirect ownership through various trusts, including 37,600 shares held by the 1988 William D. Johnston Trust, 12,857,163 shares held by the L. Lee Stryker Trust, and 2,231,173 shares held by a revocable trust.
Skeete Tatum Lisa M reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Lisa M. Skeete Tatum received an equity grant in the form of Restricted Stock Units (RSUs). She was awarded 762 shares of common stock at no stated purchase price, increasing her direct holdings to 5,205 shares after the grant.
The 762 RSUs vest in full on the earlier of the 2027 Annual Meeting of Shareholders of Stryker Corporation or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock upon vesting, aligning a portion of the director’s compensation with future company performance and share price.
Silvernail Andrew K reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Andrew K. Silvernail received an equity award of 762 Restricted Stock Units (RSUs) of Stryker common stock. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
Silvernail has voluntarily elected to defer receipt of the shares issuable upon settlement of these RSUs until his departure from the Board of Directors. Following this grant, he directly holds 18,465 shares of Stryker common stock, indicating this is a modest, routine compensation-related award relative to his overall stake.
Stryker Corporation director Rachel Ruggeri received an equity award of 762 shares of Common Stock in the form of Restricted Stock Units (RSUs). The award was granted at no cash cost to her and is classified as a grant or other acquisition, not an open-market purchase.
The RSUs vest in full on the earlier of the date of Stryker’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker Common Stock, and following this grant she holds 2,001 shares directly.
McCoy Sherilyn S reported acquisition or exercise transactions in this Form 4 filing.
STRYKER CORP director Sherilyn S. McCoy received an equity grant of 762 Restricted Stock Units. Each RSU represents a right to receive one share of Stryker common stock. The RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
McCoy has elected to defer settlement of these RSUs, so the corresponding Stryker shares will be delivered on May 1, 2031. After this grant, she holds 7,190 shares of Stryker common stock directly.
Stryker Corporation director Emmanuel Perez Maceda received an equity award in the form of Restricted Stock Units (RSUs). The award covers 762 shares of Stryker common stock and is recorded as a grant/award acquisition, not an open-market purchase or sale.
The RSUs vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock. Following this grant, Maceda directly holds 1,322 common shares.
Caforio Giovanni reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Giovanni Caforio reported an equity award in the form of Restricted Stock Units (RSUs). On May 6, 2026, he received 762 RSUs, each representing a contingent right to one share of Stryker common stock. These RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027. Following this grant, Caforio directly holds 4,530 shares of Stryker common stock.
Stryker Corporation director Mary K. Brainerd received an equity award of 762 Restricted Stock Units (RSUs) on May 6, 2026. The grant is a form of stock-based compensation and carries no cash exercise price. After this award, she directly holds 7,790 shares of Stryker common stock.
The RSUs vest in full on the earlier of the 2027 Stryker annual meeting of shareholders or May 6, 2027. Each RSU converts into one share of Stryker common stock when it vests, aligning the director’s compensation with shareholder interests over this period.